Reducing Key Toxicities with T Cell Engaging Bispecifics
Time: 8:30 am
day: Day Two
• What are the key toxicities that are common with T cell engagers?
• Exploring strategies Pfizer has used to detect and minimize potential toxicities, with a focus on solid tumor indications
• Examining how to reduce CRS with different approaches, including pharmacological blockade of cytokines